SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485
Debt
Debt-to-Equity Ratio0.30
Current Ratio5.93
Quick Ratio5.93
Price-To-Earnings
Trailing P/E Ratio-1.82
Forward P/E Ratio-2.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales331.48
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book2.49
Profitability
EPS (Most Recent Fiscal Year)($1.01)
Net Income$-25,060,000.00
Net Margins-9,450.00%
Return on Equity-78.78%
Return on Assets-43.38%
Miscellaneous
Employees19
Outstanding Shares46,840,000
Market Cap$87.13
SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions
What is SCYNEXIS's stock symbol?
SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How were SCYNEXIS's earnings last quarter?
SCYNEXIS Inc (NASDAQ:SCYX) posted its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.12) EPS for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.06. The business earned $0.06 million during the quarter, compared to analysts' expectations of $0.10 million. SCYNEXIS had a negative return on equity of 78.78% and a negative net margin of 9,450.00%. View SCYNEXIS's Earnings History.
What price target have analysts set for SCYX?
8 brokerages have issued twelve-month price objectives for SCYNEXIS's shares. Their forecasts range from $4.00 to $9.00. On average, they anticipate SCYNEXIS's share price to reach $5.6250 in the next twelve months. This suggests a possible upside of 205.7% from the stock's current price. View Analyst Ratings for SCYNEXIS.
What is the consensus analysts' recommendation for SCYNEXIS?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of SCYNEXIS's key competitors?
Some companies that are related to SCYNEXIS include GTX (GTXI), Clementia Pharmaceuticals (CMTA), BioSpecifics Technologies (BSTC), Seres Therapeutics (MCRB), Achaogen (AKAO), Sienna Biopharmaceuticals (SNNA), Paratek Pharmaceuticals (PRTK), Marinus Pharmaceuticals (MRNS), Bellicum Pharmaceuticals (BLCM), Clearside Biomedical (CLSD), Minerva Neurosciences (NERV), Corvus Pharmaceuticals (CRVS), Avid Bioservices (CDMO), Catalyst Pharmaceuticals (CPRX) and Innate Pharma (IPHYF).
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the folowing people:
- Dr. Marco Taglietti, CEO, Pres & Director (Age 58)
- Mr. Eric Francois, Chief Financial Officer (Age 43)
- Mr. David Gonzalez Angulo, Chief Medical Officer (Age 53)
- Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 40)
- Dr. Rajeshwar Motheram, VP of Pharmaceutical Devel.
Has SCYNEXIS been receiving favorable news coverage?
Media headlines about SCYX stock have trended somewhat positive on Saturday, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. SCYNEXIS earned a coverage optimism score of 0.11 on Accern's scale. They also assigned news stories about the company an impact score of 45.11 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of SCYNEXIS?
Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SCYNEXIS's stock price today?
One share of SCYX stock can currently be purchased for approximately $1.84.
How big of a company is SCYNEXIS?
SCYNEXIS has a market capitalization of $87.13 million and generates $260,000.00 in revenue each year. The company earns $-25,060,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. SCYNEXIS employs 19 workers across the globe.
How can I contact SCYNEXIS?
SCYNEXIS's mailing address is 101 HUDSON STREET SUITE 3610, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]
MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
